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Few data are available on invasive group A Streptococcus (GAS) infections (IGASIs)
in infants. We described initial clinical and laboratory features and outcomes of
<3-month-old infants hospitalized for an IGASI between 2007 and 2016 in France.
Patients were identified from the French National Reference Centre for streptococci.
IGASI was defined by the isolation of GAS from blood cultures or from other usually
sterile sites. Data collection was performed by assessing the patients’ hospitalization
reports. Twenty-six patients (15 males; 57.7%) were included. Among 19 cases with
available data, 14 (73.7%) were household contacts of a GAS infection, reaching 8/9
(88.9%) in neonates. The diagnoses were bacteremia (n = 18; 69.2%), pleural effusion
or pneumonia (n = 6; 23.1%), meningitis with brain abscess (n = 1; 3.8%), and septic
arthritis (n = 1; 3.8%). Fever (n = 10; 38.5%), hemodynamic disorders (n = 11; 42.3%),
respiratory disorders (n = 7; 26.9%), thrombocytopenia (n = 7; 26.9%), and neutropenia
(n = 5; 19.2%) were frequently observed. The main emm-genotype was emm-1 (n = 8;
30.8%). Thirteen (50.0%) infants have been admitted to the intensive care unit, and
two (7.7%) died. Respiratory disorders, high C-reactive protein level, and the need
for transfusion were significantly associated with severity. IGASI remains uncommon in
<3-month-old children but leads to a highmorbidity. Whether an antibiotic prophylaxis for
contact neonates of a patient with GAS infection decreases the risk of infection remains
to be determined.
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INTRODUCTION
Group A Streptococcus (GAS) is associated to various clinical presentations in children—from
benign to severe invasive infections. In different countries, GAS was involved in 3–5% of
bloodstream infections in children (1, 2). A rising incidence of invasive GAS infections (IGASIs)
was observed in children in the USA from 0.16 to 0.37 per 1,000 admissions between 2009 and
2016 (2).
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Neonatal infections are mainly caused by group B
Streptococcus and Escherichia coli, whereas GAS is rarely
involved (2). Very few data are available on IGASI in <3-month-
old infants (3), while their potential severity requires early
identification and appropriate management.
We aimed to describe the characteristics of IGASI in <3-
month-old infants in France.
PATIENTS AND METHODS
Inclusion Criteria and Data Collection
An IGASI was defined by the isolation of GAS from blood
cultures or from other sites that would be normally sterile. In
France, microbiology units of the whole country are encouraged
to send the invasive GAS isolates to the French National
Reference Centre for streptococci (CNR-Strep).
The records of the CNR-Strep were retrospectively queried
to identify all the neonates and infants <90 days of life who
were declared to have an IGASI between January 1, 2007, and
December 31, 2016.
Then, each center was contacted and asked to send the
hospitalization report to the first author, who collected the initial
clinical and laboratory data and the clinical outcome (length
of stay, complication, and transfer to intensive care unit) on a
standardized anonymized paper case report form. Patients or
their parents were not contacted to obtain additional or missing
data. Severe IGASIs were defined as the presence of at least one
of the following criteria: respiratory distress requiringmechanical
ventilation, hemodynamic disorders requiring fluid resuscitation,
or use of vasopressive amines, seizures, or hospitalization in the
intensive care unit.
Microbiological Analyses
Virulence genes (Table 1) as well as emm genotyping were
detected in the CNR-Strep using polymerase chain reaction, as
previously described (4, 5).
Statistical Analysis
We compared the severe and non-severe infection groups for
each characteristic found in at least five patients. Fisher’s exact
test and Mann–Whitney U-test were used for comparisons
of categorical and continuous variables, respectively. P-
values < 0.05 were considered to be statistically significant. All
statistical calculations were performed with R statistical package
3.3.2 (R Foundation for Statistical Computing, Vienna, Austria).
Ethical Statement
The study has been approved by the Robert-Debré ethical
committee (number 2016/318). As the data were obtained
retrospectively with no involvement of the patients or their
parents, no written informed consent was required by the
ethical committee, in accordance with the local legislation. An
information letter was sent to the parents. Data collection was
approved by the French National Data Protection Commission
(number 2002616v0).
TABLE 1 | Characteristics of patients with invasive Group A
Streptococcus infection.
Characteristics Number (%)
(n = 26)
Demographics
Age [median (range), in days] 38 (0; 88)
0–3 days 5 (19.2)
4–28 days 6 (23.1)
29–60 days 8 (30.8)
61–89 days 7 (26.9)
Gestational age [median (IQR), in weeks] 40 [39; 40]
Birth weight [median (IQR), in g] 3,510 (3,200; 3,800)
Birth weight [median (IQR), in percent] 66.5 (35.8–81.3)
History
Intrapartum fever 3 (11.5)
ROM <37 weeks of gestation 1 (3.8)
Prolonged ROM (>18 h) 1 (3.8)
Abnormal fetal heart rate 2 (7.7)
Neonatal cardiac surgery 2 (10.4)
Initial clinical characteristics
Time between first clinical sign and first
consultation [median (range), in days]
0 (0; 14)
Symptoms preceding admission
Fever 16 (61.5)
Difficult breathing 9 (34.6)
Poor feeding 7 (26.9)
Skin rash 5 (19.2)
Rhinitis 4 (15.4)
Hypotonia 4 (15.4)
Diarrhea 3 (11.5)
Vomiting 2 (7.7)
Seizure 1 (3.8)
General physical examination at admission
Fever 10 (38.5)
Expiratory grunting 9 (34.6)
Pallor 8 (30.8)
Pulmonary examination
Subcostal retraction 12 (46.2)
Abnormal pulmonary auscultation* 7 (26.9)
Oxygen support 5 (19.2)
Hemodynamic disorders** 11 (42.3)
Hypotonia 4 (15.4)
Cutaneous sign 11 (42.3)
Laboratory findings
Anemia‡ 5 (19.2)
White blood cell count [median (IQR), in G/L] 15.1 (13.1; 21.3)
Neutropenia# 5 (19.2)
Thrombocytopenia† 7 (26.9)
C-reactive protein
Initial [median (IQR), in mg/L] 126 (44; 161)
Maximum [median (IQR), in mg/L] 181 (108; 261)
Hyponatremia 2 (7.7)
Hypernatremia 1 (3.8)
(Continued)
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TABLE 1 | Continued
Characteristics Number (%)
(n = 26)
Hepatic cytolysis >1N± 2 (7.7)
Cholestasis (bilirubin >18 µmol/l or gamma
glutamyl transferase >2N)±
2 (7.7)
Lactic acid >7 mmol/l 3 (11,5)
Renal insufficiency (serum creatinine >N for
age)±
1 (3.8)
Radiological findings
Echocardiography
Pulmonary hypertension 4 (15.4)
Endocarditis 1 (3.8)
Pericardial effusion 1 (3.8)
Chest X-ray
Pleural effusion 5 (19.2)
Alveolar opacities 4 (15.4)
Microbiological findings
Blood culture positive for GAS 21/23 (91.3)
Cerebrospinal fluid culture positive for GAS 1/20 (5.0)
Pleural fluid culture positive for GAS 4/4 (100.0)
Joint fluid culture positive for GAS 1/1 (100.0)
Streptococcal genotyping and virulence
factors
emm 1 8 (30.8)
emm 3 2 (7.7)
emm 4 3 (11.5)
emm 6 1 (3.8)
emm 11 1 (3.8)
emm 12 3 (11.5)
emm 22 1 (3.8)
emm 28 1 (3.8)
emm 44 1 (3.8)
emm 53 1 (3.8)
emm 89 1 (3.8)
emm 104 2 (7.7)
emm 168.1 1 (3.8)
speA 10 (38.5)
speB 26 (100)
speC 8 (30,8)
smeZ-1 5 (19.2)
ssa 7 (26.9)
sic 8 (30.8)
Results are shown as number (%), except when specified.
IQR, interquartile range; ROM, rupture of membrane; GAS, group A Streptococcus; emm,
M protein coding gene; spe A or C, Streptococcal pyrogenic exotoxin genes A and
C; speB, cysteine protease SpeB gene; smeZ-1, allele 1 of streptococcal mitogenic
exotoxin Z gene; ssa, streptococcal superantigen gene; sic, streptococcal inhibitor of
complement gene.
*Decreased vesicular or sibilant murmur.
**Including tachycardia, bradycardia, hypotension, capillary refilling time >3 s, skin
mottling, cold limb extremities, hepatomegaly.
From day 0 to day 7, hemoglobin <13g/dl; and from day 7, hemoglobin <10g/dl.
#From day 0 to day 7, leukocytes <6 G/L; and from day 7, leukocytes <1.5 G/L.
†Blood Platelets <150 G/L.
±Normal values provided by laboratories.
RESULTS
Demographical and Clinical
Characteristics
Thirty-seven infants younger than 90 days old were initially
identified from 25 cities and 12 regions, but medical records
were not retrieved for 11 patients. The characteristics of the 26
included patients (15males; 57.7%), from 18 cities and 10 regions,
are shown in Table 1. None of them was preterm.
History about household contacts with GAS infection was
available in only 19 cases. Out of these, 14 (73.7%) had a
positive history: 7/19 (36.8%) were exposed to a maternal
infection (bacteremia or gynecological infection), among whom
four mothers were hospitalized for toxic shock syndrome
and two died; 5/19 (26.3%) of the household contacts had
pharyngitis/tonsillitis; and 2/19 (10.5%) had a cutaneous
infection. Among the nine neonates, a positive history of
household contacts was more common than in the 10 infants
more than 28 days old [8/9 (88.9%) and 6/10 (60%), respectively;
p= 0.3].
Among the 26 included patients, 18 (69.2%) had bacteremia,
three (11.5%) had pleural effusions or pneumonia with
bacteremia (one was complicated with endocarditis), three
(11.5%) had pleural effusions without bacteremia, one (3.8%) had
meningitis with brain abscess, and one (3.8%) had septic arthritis
of the knee. Sixteen (61.5%) out of 26 patients had fever preceding
admission, and 10/26 (38.5%) had fever at admission (Table 1).
Of note, a portal of entry was identified in 7/26 (26.9%) cases
(three impetigos, one burn, one scar, one insect bite, one cranial
hematoma due to a traumatic delivery).
Laboratory Characteristics
Laboratory findings, at presentation to the hospital, are shown in
Table 1. High C-reactive protein (CRP) levels and hematological
disorders (anemia, neutropenia, and thrombocytopenia) were
commonly observed (Table 1).
Blood cultures were collected from 22/26 (84.6%) patients and
grew GAS from 21/22 (95.5%). One out of 20 (5%) sampled
cerebrospinal fluids (CSFs) grew GAS, and this patient developed
a cerebral abscess. Four patients had positive culture from pleural
fluid (one of them also had a positive blood culture), and one
patient had a positive culture from joint fluid.
The genetic characteristics of the GAS strains are reported
in Table 1. Three emm-types (emm-1, emm-4, and emm-12)
represented more than the half of the observed genotypes
(Table 1).
Treatment and Outcome
Treatments are reported in Table 2. The most common
antibiotics used were third-generation cephalosporin [n = 20/26
(76.9%); and 15/20 (75%) were switched to intravenous
amoxicillin] and aminoglycosides [n = 19/26 (73.1%)]. Five out
of the six children, who were not treated with a third-generation
cephalosporin, received amoxicillin. Other drugs were more
rarely prescribed and were always used in addition to another
antibiotic: clindamycin (n= 3), vancomycin (n= 2), fosfomycin
(n= 1), rifampin (n= 1), and imipenem (n= 1). Complications
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TABLE 2 | Treatment and outcomes of patients with invasive group A
Streptococcus infection.
Characteristics Number (%) (n = 26)
Treatment
Intravenous antibiotics 24 (92.3)
Duration [median (range), in days] 10 (3; 49
Switch to oral amoxicillin 7 (26.9)
Duration [median (range), in days] 7 (5; 90)
Total duration of intravenous + oral
antibiotics [median (IQR), in days]
10 (7; 15)
Surgery 4 (15.4)
Transfusion 9 (34.6)
Fluid resuscitation 8 (26.9)
Catecholamine 6 (23.1)
Outcome
Length of hospitalization stay [median
(range) in days]
9 (1; 52)
Transfer to intensive care unit 13 (50.0)
Length of hospitalization stay [median
(range) in days]
12 (4; 35)
Complications
Septic shock 7 (26.9)
Seizures 3 (11.5)
Intratracheal intubation 8 (30.8)
Noninvasive ventilation 1 (3.8)
Death (within 6 months after the onset of
infection)
2 (7.7)
Results are shown as number (%), except when specified.
IQR, interquartile range.
and outcomes of the 26 patients are presented in Table 2. Overall,
13/26 (50%) patients with IGASI were considered as severe and
required admission to the intensive care unit. Four out of 26
(15.4%) patients had surgery following the onset of infection:
drainage of a cerebral abscess; arthritis; sternotomy scar revision;
and infection of burn site. One patient died 1 month after the
diagnosis of IGASI, and one patient died 5 months later due to a
non-GAS septic shock.
Factors Associated With Severity
Patients with severe IGASI more commonly had abnormal
respiratory symptoms, neutropenia, and a higher CRP level
(p< 0.05) compared to the other patients (Table 3). Streptococcus
genotypes and virulence genes were not significantly different
between severe and non-severe IGASI (Table 3). Patients with
non-severe infections had a shorter length of stay and a shorter
total duration of antibiotics than patients with severe infections
(Table 3).
DISCUSSION
In this study, we described a relatively large series of 26 cases in a
10-year period in France.
Considering the average number of births per year (∼800,000)
and the completeness of the French CNR-Strep, which has been
TABLE 3 | Comparison between patients with severe and non-severe IGASI.
Characteristics Severe patients
n = 13 (%)
Non-severe
patients
n = 13 (%)
p
Demographics
Male/female 6 (46.2) 9 (69.2) 0.43
Age [median (IQR), in
days]
43 (2; 54) 33 (15; 61) 0.5
≤28 days 5 (38.5) 3 (23.1) 0,67
Early onset infection (<3
days)
4 (30.8) 1 (7.7) 0.32
First symptoms
preceding admission
Fever 6 (46.2) 10 (76.9) 0.23
Difficult breathing 9 (69.2) 0 (0.0) <0.001
Poor feeding 4 (30.8) 3 (23.1) 1
Skin rash 2 (15.4) 3 (23.1) 1
Laboratory
Anemia 2 (15.4) 3 (23.1) 1
Neutropenia 5 (38.5) 0 (0.0) 0.04
Thrombocytopenia 6 (46.2) 1 (7.7) 0.07
CRP [median (IQR), in
mg/L]
226 (137–260) 80 (43–116) 0.047
Positive blood culture 9 (69.2) 12 (92.3) 0.32
Chest X-ray
Pleural effusion 5 (38.5) 0 (0.0) 0.04
Streptococcal
genotyping
emm1 5 (38.5) 3 (23.1) 0,67
SpeA 6 (46.2) 4 (30.8) 0.69
smeZ-1 4 (30.8) 1 (7.7) 0.32
Ssa 5 (38.5) 2 (15.4) 0.38
Sic 5 (38.5) 3 (23.1) 0.67
Treatment
Transfusions 8 (61.5) 1 (7.7) 0.01
Total duration of
intravenous + oral
antibiotics [median (IQR),
in days]
14.5 (12.3–21) 8 (7–10) 0.007
Length of stay [median
(IQR), in days]
13 (11–26) 7.5 (6–9) 0.01
IGASI, invasive group A Streptococcus infections; emm, M protein coding gene; speA
and speC, Streptococcal pyrogenic exotoxin genes A and C; smeZ-1, the allele 1 of
streptococcal mitogenic exotoxin Z gene; ssa, streptococcal superantigen gene; sic,
streptococcal inhibitor of complement gene; CRP, C-reactive protein.
estimated to an average rate of 28%, we could estimate the
incidence of IGASI in <3-month-old children at 1.6/100,000
infants per year.
Although uncommon, our study has confirmed that IGASIs
are frequently associated with clinical severity in <3-month-old
infants. We found that bacteremia with no focal sign and pleuro-
pneumonia were the most common clinical presentations,
accounting for almost 90% of cases. Clinical characteristics were
similar to those published in a previous review (3). Half of
patients were considered as affected by a severe disease and
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exhibited more commonly respiratory disorders, neutropenia,
and high CRP level and needed more transfusion and longer
duration of antibiotics and length of stay compared to the
patients with non-severe IGASI.
We observed that the emm-1,−4, and−12 represented more
than half of the genotypes, similarly to the French epidemiology,
described by Plainvert et al. (6) in patients younger than 15 years
old with IGASI. However, no association was observed between
severity and the genotypes or the presence of certain virulence
genes, in contrast to previous studies in children (4). This may
suggest an altered balance between host defenses in this group of
age and GAS virulence.
Of note, 73.7% of the infants were household contacts of GAS
infection, reaching 88.9% among neonates. This is in accordance
with a study evaluating household transmission of invasive GAS
in England; authors described that the risk of transmission of
invasive GASI was substantially elevated in households after a
single case, particularly for mothers and neonates during the
neonatal period (risk ratio: 11.9; 95% confidence interval 2.0–
70.3). In this population, the theoretical number needed to treat
to prevent one secondary case using antibiotic prophylaxis was
50 compared to 271 for the overall population (7). Although
not systematically applied in the United Kingdom and the
Ireland, these countries recommend prophylaxis for postpartum
mothers and neonates when the other develops IGASI (7). This
is not recommended in France yet, and no children of our
study received prophylaxis. Our study may suggest the need of
an appropriate prophylaxis in the contact neonates of a GAS
infection index case. However, given that our study did not allow
describing whether otherwise healthy newborns in contact with
people with GAS infection do not exhibit symptoms, further
studies would be necessary to explore that hypothesis.
Our study has several limitations. Data collection was
retrospective, and only 26 patients have been included despite
a 10-year period in the whole country. Moreover, we could not
describe the characteristics of 11 patients identified by the CNR-
Strep due to the impossibility to obtain themedical records. Thus,
our results may not be generalizable.
In conclusion, IGASI in <3-month-old infants remains
uncommon, but 50% of patients are severely ill. The very high
proportion of GAS infection in the household of these neonates
suggests a need to assess whether a systematic prophylaxis and
close follow-up allow avoiding these severe infections.
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